Congestive heart failure is a devastating disease that is characterized by impaired left ventricular function, compromising the heart’s ability to pump blood – taking more lives than all forms of cancer combined. 

Carvedilol broadly belongs to the class of drugs known as beta-blockers, but it also has several other important pharmacological activities that distinguish it from that class, making the drug particularly useful, and highly effective, in the treatment of congestive heart failure.

Join us in conversation as we discuss the sixteen-year journey behind the discovery, development, and global regulatory approval of this life-saving drug and its journey to being listed in the World Health Organization’s List of Essential Medicines.

Speaker